Misplaced Pages

Rociverine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 15:13, 29 March 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits removed Category:Cyclopentanes using HotCat← Previous edit Revision as of 05:45, 27 December 2024 edit undoD6dmso (talk | contribs)33 editsNo edit summaryTag: Visual editNext edit →
(21 intermediate revisions by 16 users not shown)
Line 1: Line 1:
{{short description|Chemical compound}}
{{multiple issues|
{{context|date=April 2014}}
{{one source|date=March 2021}}
}}
{{Drugbox {{Drugbox
| Watchedfields = changed
| verifiedrevid = 376118658 | verifiedrevid = 443791079
| IUPAC_name = 2-(diethylamino)-1-methylethyl (1''S'')-1-hydroxy-1,1'-bi(cyclohexyl)-2-carboxylate
|synonyms = <small>(1''S'')-1-(diethylamino)propan-2-yl 1-hydroxybi(cyclohexane)-2-carboxylate</small> | IUPAC_name = 2-(diethylamino)-1-methylethyl (1''S'')-1-hydroxy-1,1'-bi(cyclohexyl)-2-carboxylate
| image = Rociverine.png | image = Rociverine.png

⚫ | CAS_number = 53716-44-2
<!--Clinical data-->
⚫ | ATC_prefix = A03
| ATC_suffix = AA06 | tradename =
| Drugs.com = {{drugs.com|international|rociverine}}
⚫ | PubChem = 68705
| DrugBank = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫ | pregnancy_US = <!-- A / B / C / D / X -->
⚫ | C=20|H=37|N=1|O=3
⚫ | pregnancy_category =
| molecular_weight = 339.51 g/mol
⚫ | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
⚫ | bioavailability =
⚫ | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫ | protein_bound =
⚫ | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
⚫ | metabolism =
⚫ | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫ | elimination_half-life =
⚫ | legal_status =
⚫ | excretion =
⚫ | routes_of_administration =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

⚫ | pregnancy_US = <!-- A / B / C / D / X -->
<!--Pharmacokinetic data-->
⚫ | pregnancy_category=
⚫ | bioavailability =
⚫ | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
⚫ | protein_bound =
⚫ | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫ | metabolism =
⚫ | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
⚫ | elimination_half-life =
⚫ | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫ | excretion =
⚫ | legal_status =

⚫ | routes_of_administration =
<!--Identifiers-->
⚫ | CAS_number = 53716-44-2
⚫ | ATC_prefix = A03
| ATC_suffix = AA06
⚫ | PubChem = 68705
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = VI08KS44V0

<!--Chemical data-->
⚫ | C=20 | H=37 | N=1 | O=3
| synonyms = <small>(1''S'')-1-(diethylamino)propan-2-yl 1-hydroxybi(cyclohexane)-2-carboxylate</small>
}} }}
{{Unreferenced|date=February 2009}}
'''Rociverine''' is an ].


'''Rociverine''' is an antispasmodic drug used to treat urinary, gastrointestinal and biliary spasms.<ref>{{Cite web |title=Rociverine |url=https://go.drugbank.com/drugs/DB13581}}</ref> It is ] drug.<ref name="pmid582702">{{cite journal | vauthors = Toson G, Schiantarelli P, Murmann W | title = Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity | journal = Arzneimittel-Forschung | volume = 28 | issue = 7 | pages = 1130–42 | date = 1978 | pmid = 582702 | doi = | url = }}</ref>
⚫ {{Drugs for functional gastrointestinal disorders}}


The (1R,2R) compound showed 240-fold greater affinity for the muscarinic receptor, but the (1S,2S) compound showed the best selectivity. <ref>{{Cite journal |last=Barbier |first=Pascaline |last2=Renzetti |first2=Anna R. |last3=Turbanti |first3=Luigi |last4=Di Bugno |first4=Cristina |last5=Fornai |first5=Francesco |last6=Vaglini |first6=Francesca |last7=Maggio |first7=Roberto |last8=Corsini |first8=Giovanni U. |date=1995-07 |title=Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine |url=https://linkinghub.elsevier.com/retrieve/pii/0922410695900241 |journal=European Journal of Pharmacology: Molecular Pharmacology |language=en |volume=290 |issue=2 |pages=125–132 |doi=10.1016/0922-4106(95)90024-1}}</ref>


==References==
{{Reflist}}



⚫ {{Drugs for functional gastrointestinal disorders}}
{{Muscarinic acetylcholine receptor modulators}}

]
] ]
] ]
] ]
] ]



{{gastrointestinal-drug-stub}} {{gastrointestinal-drug-stub}}

]

Revision as of 05:45, 27 December 2024

Chemical compound
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article provides insufficient context for those unfamiliar with the subject. Please help improve the article by providing more context for the reader. (April 2014) (Learn how and when to remove this message)
This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.
Find sources: "Rociverine" – news · newspapers · books · scholar · JSTOR (March 2021)
(Learn how and when to remove this message)
Pharmaceutical compound
Rociverine
Clinical data
Other names(1S)-1-(diethylamino)propan-2-yl 1-hydroxybi(cyclohexane)-2-carboxylate
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • 2-(diethylamino)-1-methylethyl (1S)-1-hydroxy-1,1'-bi(cyclohexyl)-2-carboxylate
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.053.356 Edit this at Wikidata
Chemical and physical data
FormulaC20H37NO3
Molar mass339.520 g·mol
  (verify)

Rociverine is an antispasmodic drug used to treat urinary, gastrointestinal and biliary spasms. It is antimuscarinic drug.

The (1R,2R) compound showed 240-fold greater affinity for the muscarinic receptor, but the (1S,2S) compound showed the best selectivity.

References

  1. "Rociverine".
  2. Toson G, Schiantarelli P, Murmann W (1978). "Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity". Arzneimittel-Forschung. 28 (7): 1130–42. PMID 582702.
  3. Barbier, Pascaline; Renzetti, Anna R.; Turbanti, Luigi; Di Bugno, Cristina; Fornai, Francesco; Vaglini, Francesca; Maggio, Roberto; Corsini, Giovanni U. (1995-07). "Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine". European Journal of Pharmacology: Molecular Pharmacology. 290 (2): 125–132. doi:10.1016/0922-4106(95)90024-1. {{cite journal}}: Check date values in: |date= (help)


Drugs for functional gastrointestinal disorders (A03)
Drugs for
functional
bowel
disorders
Antimuscarinics
Tertiary
amino group
Quaternary
ammonium
compounds
Phosphodiesterase
inhibitors
Acting on
serotonin receptors
Other
Belladonna
and derivatives
(antimuscarinics)
Propulsives
Muscarinic acetylcholine receptor modulators
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Nicotinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: